Intestinal Infection by Entamoeba: Complete ICD-11 Coding Guide (1A36.0)

1. Introduction

Intestinal infection by Entamoeba, coded as 1A36.0 in the International Classification of Diseases (ICD-11), represents a parasitic condition that affects the human gastrointestinal tract, caused primarily by Entamoeba histolytica. This protozoan infection constitutes a significant public health problem in regions with inadequate sanitary conditions, affecting millions of people annually worldwide.

The clinical importance of this infection lies not only in its considerable prevalence, but also in its potential to cause serious complications when not diagnosed and treated appropriately. Entamoeba histolytica can cause presentations ranging from asymptomatic cases to severe manifestations of amebic dysentery, with risk of intestinal perforation and peritonitis. Transmission occurs primarily through the fecal-oral route, via ingestion of water or food contaminated with parasite cysts.

The impact on public health is particularly relevant in communities with deficient sanitary infrastructure, where contamination of water sources facilitates the dissemination of the etiological agent. Healthcare workers should be alert to risk factors, including travel to endemic areas, precarious housing conditions, and inadequate food hygiene practices.

Correct coding of this condition is critical for multiple purposes: it enables appropriate epidemiological tracking, facilitates proper allocation of public health resources, ensures correct reimbursement of diagnostic and therapeutic procedures, and contributes to epidemiological research that guides health policies. Precise distinction between intestinal and extraintestinal Entamoeba infections is fundamental for appropriate treatment and correct prognosis.

2. Correct ICD-11 Code

Code: 1A36.0

Description: Intestinal infection by Entamoeba

Parent category: 1A36 - Amebiasis

This specific code belongs to the chapter on infectious or parasitic diseases of ICD-11 and was developed to exclusively identify the intestinal manifestations of Entamoeba infection. The hierarchical structure of the classification positions this code under the broader category of amebiasis (1A36), allowing both specificity and flexibility in coding.

The designation 1A36.0 should be used when confirmed or strongly suspected involvement is limited to the gastrointestinal tract, including manifestations such as amebic colitis, amebic dysentery, and asymptomatic carriers with parasitological evidence of intestinal infection. This code encompasses the entire spectrum of severity of intestinal manifestations, from mild infections to severe fulminant colitis.

Precision in the use of this code is essential to differentiate intestinal from extraintestinal manifestations, which receive distinct coding. ICD-11 promotes a more granular approach to the classification of parasitic diseases, reflecting the evolution of medical knowledge regarding the pathogenesis, clinical manifestations, and specific therapeutic approaches for each presentation of amebiasis.

3. When to Use This Code

Code 1A36.0 should be applied in specific clinical scenarios where there is evidence of intestinal infection by Entamoeba. Below, we present detailed practical situations:

Scenario 1: Acute Amebic Dysentery Patient presents with acute onset of bloody diarrhea with mucus (dysentery), accompanied by cramping abdominal pain, tenesmus, and low-grade fever. Parasitological stool examination demonstrates the presence of Entamoeba histolytica trophozoites with phagocytosed red blood cells, or positive fecal antigen test for E. histolytica. There is no evidence of extraintestinal involvement. This is the classic scenario for using code 1A36.0.

Scenario 2: Chronic Amebic Colitis Patient with a history of intermittent diarrhea for several weeks or months, with periods of improvement and worsening, accompanied by abdominal discomfort and weight loss. Colonoscopy reveals characteristic ulcers ("flask-shaped") and biopsy confirms the presence of Entamoeba trophozoites in the intestinal mucosa. Code 1A36.0 is appropriate even in chronic presentations when limited to the intestine.

Scenario 3: Asymptomatic Carrier Identified Asymptomatic individual undergoing parasitological screening (for example, food handler, preoperative evaluation, or contact investigation) presents a positive result for Entamoeba histolytica cysts on stool examination. Even in the absence of symptoms, when there is laboratory confirmation of the presence of the parasite in the intestinal tract, code 1A36.0 should be used to document the infection.

Scenario 4: Intestinal Ameboma Patient develops an inflammatory tumor mass in the colon (ameboma) as a complication of intestinal amebic infection, manifesting as partial intestinal obstruction or palpable mass. Imaging studies show focal lesion in the colon and parasitological investigation confirms amebic etiology. Since the ameboma represents a complication of intestinal infection, code 1A36.0 remains appropriate.

Scenario 5: Fulminant Amebic Colitis Severe presentation with profuse diarrhea, severe dehydration, abdominal distension, and signs of toxemia. There is risk of toxic megacolon or intestinal perforation. Laboratory tests confirm Entamoeba histolytica infection. Despite the severity, as long as the disease remains confined to the intestine (without hepatic abscess or other extraintestinal manifestations), code 1A36.0 is correct.

Scenario 6: Recurrence of Intestinal Infection Patient previously treated for intestinal amebiasis presents with a new episode of gastrointestinal symptoms with parasitological confirmation of reinfection or recrudescence. Code 1A36.0 should be used again, and recurrent episode specifiers may be added if available in the documentation system.

4. When NOT to Use This Code

It is essential to recognize situations where code 1A36.0 is not appropriate, avoiding coding errors that may compromise medical records and epidemiological data:

Extraintestinal Infections by Entamoeba When the patient develops amebic liver abscess, brain abscess, lung abscess, or any manifestation outside the gastrointestinal tract, even if secondary to the initial intestinal infection, the correct code becomes 1A36.1 (Extraintestinal infections by Entamoeba). The presence of extraintestinal complications changes the primary coding, even though concomitant intestinal involvement may be present.

Infection by Entamoeba dispar or Entamoeba moshkovskii These species of Entamoeba are morphologically similar to E. histolytica, but do not cause invasive disease. When molecular or specific immunological tests identify these non-pathogenic species, code 1A36.0 should not be used. Many health systems consider these infections as findings without clinical significance, not requiring specific treatment or coding.

Other Causes of Dysentery Dysentery caused by Shigella, Salmonella, Campylobacter, enteroinvasive Escherichia coli, or other bacterial pathogens requires specific codes for each etiological agent. Differentiation is made through bacterial cultures and parasitological tests. The presence of large quantities of fecal leukocytes suggests bacterial etiology, while visualization of trophozoites with phagocytosed red blood cells is characteristic of amebiasis.

Ulcerative Colitis or Crohn's Disease Chronic inflammatory bowel diseases may present symptoms similar to amebic colitis, including bloody diarrhea and colonoscopic ulcers. Differentiation requires negative parasitological investigation and histopathological findings characteristic of inflammatory bowel disease. These conditions have completely different codes in ICD-11.

Irritable Bowel Syndrome with Diarrhea Patients with chronic functional gastrointestinal symptoms without parasitological evidence of infection should not receive code 1A36.0, even if they present with intermittent diarrhea. The diagnosis of amebiasis requires objective laboratory confirmation of the presence of the parasite.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

Diagnostic confirmation of intestinal infection by Entamoeba requires a systematic approach. Begin with detailed clinical evaluation, investigating symptoms such as diarrhea (especially if bloody), abdominal pain, tenesmus, fever, and weight loss. Question regarding risk factors: recent travel to endemic areas, consumption of possibly contaminated water or food, and sanitary conditions.

Diagnostic tools include: parasitological examination of feces (ideally three samples on alternate days), antigen detection of E. histolytica in feces by immunoassay, molecular tests (PCR) to differentiate E. histolytica from non-pathogenic species, serology for anti-E. histolytica antibodies (more useful in extraintestinal infections), and colonoscopy with biopsy when indicated. Visualization of trophozoites with phagocytized red blood cells is highly specific for E. histolytica.

Step 2: Verify Specifiers

Document the severity of clinical presentation: mild (minimal symptoms, ambulatory patient), moderate (significant symptoms requiring hydration and monitoring), or severe (severe dehydration, toxemia, risk of complications). Record symptom duration: acute (less than four weeks) or chronic (more than four weeks).

Identify specific characteristics such as presence of blood and mucus in feces, frequency of bowel movements, degree of dehydration, presence of fever, and nutritional status. For asymptomatic carriers, document the context of discovery (screening, contact investigation, preoperative examination). These specifiers, although they do not change the main code 1A36.0, are essential for complete clinical documentation.

Step 3: Differentiate from Other Codes

Differentiation from 1A36.1 (Extraintestinal Entamoeba infections): The fundamental distinction is the anatomical location of involvement. Use 1A36.0 when infection is confined to the gastrointestinal tract. If there is hepatic, pulmonary, cerebral abscess, or any extraintestinal manifestation, even with concomitant intestinal symptoms, the correct code is 1A36.1. Imaging studies (ultrasonography, computed tomography) are essential to exclude extraintestinal involvement, especially hepatic, which is the most common extraintestinal complication.

Practical rule: intestine only = 1A36.0; any organ beyond the intestine = 1A36.1. In cases of doubt, performing abdominal ultrasonography to investigate hepatic abscess is recommended before finalizing coding.

Step 4: Required Documentation

For appropriate coding, medical documentation must include:

Mandatory checklist:

• Detailed description of symptoms presented and their duration
• Results of parasitological examination of feces (method used, number of samples, specific results)
• Results of immunological or molecular tests, if performed
• Description of colonoscopic and histopathological findings, when applicable
• Exclusion of extraintestinal involvement (document imaging studies performed)
• Risk factors identified and epidemiological history
• Assessment of clinical severity
• Differential diagnoses considered and excluded

The record must be sufficiently detailed to justify the chosen code and allow for subsequent audit. Avoid vague terms such as "intestinal parasitosis" without specifying the etiological agent. Precise documentation of "intestinal infection by Entamoeba histolytica" or "intestinal amebiasis" with laboratory evidence is ideal.

6. Complete Practical Example

Clinical Case

A 42-year-old male patient presents to the emergency department with a complaint of diarrhea for eight days. He reports liquid bowel movements with the presence of blood and mucus, approximately 8-10 times per day, accompanied by cramping abdominal pain, mainly in the right iliac fossa and hypogastrium. He refers to a sensation of incomplete evacuation (tenesmus) and intermittent low-grade fever. He denies vomiting but reports decreased appetite and weight loss of approximately three kilograms since symptom onset.

In the epidemiological history, the patient mentions returning three weeks ago from travel to a region with poor sanitary conditions, where he consumed untreated spring water and food from street vendors. He denies recent use of antibiotics or anti-inflammatory drugs.

On physical examination, the patient appears in fair general condition, mucous membranes slightly pale and dehydrated, heart rate 92 bpm, blood pressure 110/70 mmHg, axillary temperature 37.8°C. Abdomen slightly distended, increased bowel sounds, pain on deep palpation in the right iliac fossa and hypogastrium, without signs of peritoneal irritation. Digital rectal examination reveals the presence of stool with blood and mucus.

Laboratory tests were requested: complete blood count showing leukocytes 11,500/mm³ with left shift, hemoglobin 12.8 g/dL, normal platelets. Parasitological stool examination in three consecutive samples revealed the presence of Entamoeba histolytica trophozoites with phagocytosed red blood cells in the second and third samples. Antigen detection test for E. histolytica in stool was positive. Stool culture negative for pathogenic bacteria.

Abdominal ultrasound performed to investigate possible hepatic involvement showed liver of normal dimensions and echotexture, without focal lesions, normal gallbladder and biliary ducts, spleen and kidneys without alterations.

Coding Step by Step

Criteria Analysis:

1. Diagnostic confirmation: Presence of E. histolytica trophozoites with phagocytosed red blood cells on parasitological examination (gold standard criterion) and positive antigen test definitively confirm the infection.

2. Anatomical location: Symptoms exclusively gastrointestinal (bloody diarrhea, abdominal pain, tenesmus). Normal abdominal ultrasound excludes hepatic or other organ involvement.

3. Severity: Moderate presentation with mild dehydration, without signs of severe toxemia or complications such as perforation.

4. Exclusion of differential diagnoses: Negative stool culture excludes shigellosis and other bacterial causes of dysentery.

Code Selected: 1A36.0 - Intestinal infection by Entamoeba

Complete Justification:

The code 1A36.0 is appropriate because:

• There is unequivocal laboratory confirmation of Entamoeba histolytica infection
• The involvement is exclusively intestinal (amebic colitis)
• There is no evidence of extraintestinal manifestations
• The clinical presentation is compatible with amebic dysentery
• The epidemiological risk factors corroborate the diagnosis

Complementary Codes:

Although the primary code is 1A36.0, additional codes may be considered for:

• Dehydration (5C70)
• Mild anemia secondary to blood loss (3A00)
• Codes for procedures performed (laboratory tests, ultrasound)

The documentation should include all laboratory findings, justification for code selection, and the therapeutic plan instituted (usually metronidazole or tinidazole followed by paromomycin to eliminate cysts).

7. Related Codes and Differentiation

Within the Same Category

1A36.1: Extraintestinal infections by Entamoeba

The main differentiation between 1A36.0 and 1A36.1 is based exclusively on the anatomical location of involvement. Code 1A36.1 should be used when there are manifestations outside the gastrointestinal tract, with amebic liver abscess being the most common presentation, followed by pulmonary, cerebral, cutaneous, or other organ involvement.

When to use 1A36.1 versus 1A36.0:

• Patient with amebic diarrhea who develops liver abscess: use 1A36.1 (the extraintestinal complication becomes the primary diagnosis)
• Patient with amebic liver abscess without current intestinal symptoms: use 1A36.1
• Patient with only amebic colitis, even if severe: use 1A36.0

The distinction is critical because extraintestinal manifestations frequently require prolonged therapeutic approach and may require percutaneous or surgical drainage, in addition to pharmacological treatment. Serology for anti-E. histolytica antibodies is more sensitive in extraintestinal infections (especially liver abscess) than in isolated intestinal infections.

Differential Diagnoses

Shigellosis (Shigella infection): Presents with clinical picture very similar to amebic dysentery, with bloody diarrhea, fever, and abdominal pain. Differentiation requires positive stool culture for Shigella and negative parasitological examination. Shigellosis tends to present with higher fever, more abrupt onset, and greater amount of leukocytes in stool.

Ulcerative colitis: Chronic inflammatory bowel disease that can mimic chronic amebic colitis. Differentiation requires negative parasitological examination, characteristic histopathological findings (chronic inflammation, crypt abscesses, architectural distortion), and typical colonoscopic pattern. Ulcerative colitis usually has a recurrent-remitting course over years.

Pseudomembranous colitis (Clostridioides difficile): Should be considered especially in patients with recent antibiotic use. Detection of C. difficile toxins in stool and negative parasitological examination establish the correct diagnosis.

Crohn's disease with colonic involvement: Differentiated by transmural inflammation pattern, presence of non-caseating granulomas on histology, segmental involvement, and negative parasitological examination.

8. Differences with ICD-10

In the International Classification of Diseases, 10th revision (ICD-10), intestinal infection by Entamoeba was coded as A06.0 - Acute amebic dysentery for acute presentations or A06.1 - Chronic intestinal amebiasis for chronic cases, requiring the coder to differentiate between acute and chronic presentations of the same condition.

ICD-11 simplified this classification by creating the single code 1A36.0 - Intestinal infection by Entamoeba, which encompasses all intestinal manifestations regardless of duration or severity. This change reflects the understanding that the distinction between acute and chronic is not always clinically clear and that both presentations essentially represent the same pathological entity with variable spectrum of manifestations.

Main practical changes:

The elimination of the need to classify as acute versus chronic simplifies the coding process and reduces ambiguities. In ICD-10, there was uncertainty about which code to use for subacute presentations or for asymptomatic carriers. ICD-11 resolves this with a single code that encompasses the entire spectrum.

The hierarchical structure of ICD-11 is more logical, with clear separation between intestinal manifestations (1A36.0) and extraintestinal (1A36.1), whereas ICD-10 had multiple codes for different complications. The parent category 1A36 (Amebiasis) groups all manifestations, facilitating epidemiological analyses.

The practical impact includes the need to update health information systems, training of coding professionals, and adjustments in institutional protocols. For purposes of transition and comparability of historical data, mapping tools between ICD-10 and ICD-11 are essential for temporal trend analyses.

9. Frequently Asked Questions

1. How is the definitive diagnosis of intestinal infection by Entamoeba made?

Definitive diagnosis requires laboratory confirmation of the presence of Entamoeba histolytica. The traditional method is parasitological examination of feces, ideally with collection of three samples on alternate days, increasing diagnostic sensitivity. Microscopic visualization of trophozoites containing phagocytosed red blood cells is highly specific for E. histolytica. Tests for detection of E. histolytica antigens in feces by immunoassay are more sensitive and specific than conventional microscopy, differentiating E. histolytica from non-pathogenic species. Molecular tests (PCR) represent the gold standard when available, allowing precise species identification. In selected cases, colonoscopy with biopsy can be performed, revealing characteristic ulcers and allowing histopathological identification of the parasite.

2. Is treatment available in public health systems?

Medications for treatment of intestinal amebiasis, particularly metronidazole and tinidazole, are widely available in public health systems in most countries, being considered essential medicines by the World Health Organization. Standard treatment consists of two phases: use of nitroimidazoles (metronidazole or tinidazole) to eliminate tissue trophozoites, followed by a luminal agent (paromomycin, iodoquinol, or diloxanide furoate) to eradicate intestinal cysts and prevent relapse. The availability of luminal agents may be more limited in some locations, but therapeutic alternatives exist. Access to treatment is generally good, although it may vary according to local resources and specific health policies.

3. How long does treatment last?

Typical treatment of intestinal infection by Entamoeba lasts 10 to 20 days, depending on the protocol used. The initial phase with nitroimidazoles (metronidazole or tinidazole) generally lasts 5 to 10 days. Metronidazole is administered three times daily for 7-10 days, while tinidazole can be used in a single daily dose for 3-5 days. After completing tissue therapy, a luminal agent is recommended for an additional 7-10 days to eliminate cysts and prevent relapse. Asymptomatic carriers may be treated with luminal agent alone. Control parasitological examination should be performed 2-4 weeks after completion of treatment to confirm eradication. Severe or complicated cases may require longer treatment periods.

4. Can this code be used in medical certificates and work-related documents?

Yes, code 1A36.0 can and should be used in official medical documentation, including certificates for work purposes, when appropriate. Intestinal amebiasis is a condition that frequently causes temporary work incapacity due to significant gastrointestinal symptoms. The period of absence varies according to severity: mild cases may require 3-5 days, moderate cases 7-10 days, and severe cases may require longer absence. Documentation should include the ICD-11 code and description of the condition in a way that preserves patient confidentiality as needed. For professions involving food handling, absence should extend until confirmation of parasitological cure to prevent transmission.

5. Do asymptomatic patients with positive test results need treatment?

Yes, asymptomatic carriers of Entamoeba histolytica should receive treatment, even in the absence of symptoms. The justification is twofold: first, these individuals represent reservoirs of infection and can transmit the parasite to other people through environmental contamination; second, they may develop symptomatic disease later. Treatment of asymptomatic carriers is especially important for food handlers, healthcare professionals, and individuals in institutional settings. The therapeutic regimen for asymptomatic carriers can be simplified, using only luminal agent (paromomycin or iodoquinol) without the need for nitroimidazole, since there is no invasive tissue disease. Code 1A36.0 remains appropriate even for asymptomatic carriers.

6. What is the difference between Entamoeba histolytica and Entamoeba dispar?

Entamoeba histolytica and Entamoeba dispar are morphologically identical species under light microscopy, but with completely different pathogenic potential. E. histolytica is pathogenic, capable of invading the intestinal mucosa and causing disease, while E. dispar is considered non-pathogenic, colonizing the intestine without causing tissue damage. Differentiation requires specific immunological tests (detection of E. histolytica-specific antigens) or molecular tests (PCR). This distinction is clinically important because only E. histolytica requires treatment. When conventional examinations identify "Entamoeba histolytica/dispar" without differentiation, in symptomatic patients treatment is generally indicated presuming E. histolytica, while in asymptomatic individuals additional tests can be considered to confirm the species before treating.

7. What are the main risk factors for acquiring this infection?

The main risk factors include: consumption of untreated water or contaminated food, especially raw vegetables washed with contaminated water; travel to areas with inadequate basic sanitation; close contact with infected individuals; housing conditions with deficient sanitary infrastructure; inadequate personal hygiene practices, particularly hand washing; institutionalization (nursing homes, orphanages, psychiatric institutions); men who have sex with men (fecal-oral transmission during sexual practices); and immunosuppression, although amebiasis is not considered a classic opportunistic infection. Person-to-person transmission is possible through fecal-oral contact, making outbreaks possible in crowded environments with inadequate hygiene.

8. Is reinfection possible after successful treatment?

Yes, reinfection by Entamoeba histolytica is possible after successful treatment, as infection does not confer lasting protective immunity. Individuals who remain exposed to the same risk factors that led to the initial infection can become reinfected. Prevention of reinfection depends on measures such as: exclusive consumption of treated or boiled water, adequate food hygiene (especially raw vegetables), rigorous hand washing, improvement of sanitary conditions, and treatment of other family members or close contacts when indicated. In endemic areas, recurrent episodes are relatively common. The distinction between relapse (treatment failure) and reinfection can be clinically difficult, but both require a new treatment cycle. Code 1A36.0 should be used again in cases of documented reinfection.

---

Conclusion:

Appropriate coding of intestinal infection by Entamoeba using ICD-11 code 1A36.0 requires clear understanding of diagnostic criteria, precise differentiation of extraintestinal manifestations, and complete documentation of clinical and laboratory findings. This article provides practical guidance for healthcare professionals to ensure accurate coding, contributing to quality medical records, reliable epidemiological data, and appropriate care for patients affected by this important intestinal parasitosis.

External References

This article was prepared based on reliable scientific sources:

1. 🌍 WHO ICD-11 - Intestinal infection by Entamoeba
2. 🔬 PubMed Research on Intestinal infection by Entamoeba
3. 🌍 WHO Health Topics
4. 📋 CDC - Centers for Disease Control
5. 📊 Clinical Evidence: Intestinal infection by Entamoeba
6. 📋 Ministry of Health - Brazil
7. 📊 Cochrane Systematic Reviews

References verified on 2026-02-04